AstraZeneca Pharma India Ltd has accepted the resignations of two senior management personnel, Ms. Aditi Mehta and Mr. Srikanth B.S., who are leaving to pursue career opportunities outside the organisation. The departures were disclosed in a regulatory filing submitted on June 12, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The exits impact key leadership functions within the Oncology Business Unit and India Operations.

Senior Leadership Departures

Ms. Aditi Mehta served as Business Unit Director of the Oncology Business Unit. She completed her handover period and was relieved from her duties effective the close of business hours on June 12, 2026. The company stated that it is in the process of identifying a suitable replacement to ensure continuity in its oncology operations.

Mr. Srikanth B.S. held the position of Site Lead, India Operations. He will be relieved following the completion of his handover period, with his cessation effective the close of business hours on June 15, 2026. No specific details regarding the recruitment process for his role were disclosed in the filing.

Resignation Details at a Glance

The following table summarises the key details of both resignations as disclosed in the regulatory filing:

Regulatory Compliance

The filing was signed by Tanya Sanish, Company Secretary and Compliance Officer of AstraZeneca Pharma India Limited. The disclosures were made in accordance with SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026.

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organization (CDSCO) to import and sell Trastuzumab deruxtecan for an additional indication, specifically for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. The approval, granted on June 10, 2026, covers the 100 mg/5mL vial lyophilized powder for concentrate for solution for infusion under the brand name Enhertu®. This regulatory clearance allows the company to market the drug in India for the specified indication, subject to the receipt of related statutory approvals.

Regulatory Approval Details

The authorization from the Directorate General of Health Services, Government of India, permits AstraZeneca Pharma India to import for sale and distribution of the drug. The approval specifically targets the use of Trastuzumab deruxtecan in combination with pertuzumab.

Significance of the Approval

The regulatory green light represents a key step in expanding the availability of Enhertu® to the Indian market for this specific patient group. The approval underscores AstraZeneca Pharma India's continued efforts to broaden its pharmaceutical offerings in the country through the necessary regulatory channels.